Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 7/20 | 0.83 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.77 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.77 |
| ▸ | GSK3A | P49840 | 3/20 | 0.61 |
| ▸ | GSK3B | P49841 | 3/20 | 0.61 |
| ▸ | INSR | P06213 | 3/20 | 0.61 |
| ▸ | IGF1R | P08069 | 3/20 | 0.61 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.59 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.53 |
| ▸ | RXRA | P19793 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12990070 | 1.00 | PIK3CG (0.83) | PIK3CGHSPD1HSPE1GSK3AGSK3B | |
| SCHEMBL3366739 | 1.00 | PIK3CG (0.83) | PIK3CGHSPD1HSPE1GSK3AGSK3B | |
| SCHEMBL4978943 | 0.91 | PIK3CG (1.00) | PIK3CGHSPD1HSPE1GSK3AGSK3B | |
| SCHEMBL4978949 | 0.91 | PIK3CG (1.00) | PIK3CGHSPD1HSPE1GSK3AGSK3B | |
| SCHEMBL3364886 | 0.87 | PIK3CG (1.00) | PIK3CGHSPD1HSPE1GSK3AGSK3B | |
| SCHEMBL12989666 | 0.87 | PIK3CG (1.00) | PIK3CGHSPD1HSPE1GSK3AGSK3B | |
| SCHEMBL3364888 | 0.87 | PIK3CG (1.00) | PIK3CGHSPD1HSPE1GSK3AGSK3B | |
| SCHEMBL30517269 | 0.87 | PIK3CG (1.00) | PIK3CGHSPD1HSPE1GSK3AGSK3B | |
| SCHEMBL30517272 | 0.87 | PIK3CG (1.00) | PIK3CGHSPD1HSPE1GSK3AGSK3B | |
| SCHEMBL12990247 | 0.86 | PIK3CG (0.82) | PIK3CGHSPD1HSPE1GSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331315-A1 | RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-12-30 | — | — | US | disclosed |
| WO-2010148351-A1 | RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331315-A1 | RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | PIM2, PIM1, CDK2 | PIK3CG 456/4885HSPD1 1307/4885HSPE1 1252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.